Similarly, there are other studies associating CDKN3 overexpression with poor survival in nasopharyngeal carcinoma, lung adenocarcinoma, breast, bladder, and cervical cancer [71,72,73,74,75]. Here, CDKN3 is linked to lung adenocarcinoma.